Financial Analysis: BioNxt Solutions (OTCMKTS:BNXTF) versus Corbus Pharmaceuticals (NASDAQ:CRBP)

Corbus Pharmaceuticals (NASDAQ:CRBP) and BioNxt Solutions (OTCMKTS:BNXTF) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, risk, dividends and profitability.

Earnings and Valuation

This table compares Corbus Pharmaceuticals and BioNxt Solutions”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54 million	($5.98)	-1.44
BioNxt Solutions	$20,000.00	2,388.56	-$3.88 million	($0.04)	-9.75

BioNxt Solutions has higher revenue and earnings than Corbus Pharmaceuticals. BioNxt Solutions is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 3.6% of Corbus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

Corbus Pharmaceuticals has a beta of 2.84, indicating that its stock price is 184% more volatile than the S&P 500. Comparatively, BioNxt Solutions has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.

Profitability

This table compares Corbus Pharmaceuticals and BioNxt Solutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-65.76%	-57.88%
BioNxt Solutions	N/A	N/A	-709.36%

Analyst Ratings

This is a breakdown of current ratings for Corbus Pharmaceuticals and BioNxt Solutions, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2	0	6	2	2.80
BioNxt Solutions	0	0	0	0	0.00

Corbus Pharmaceuticals presently has a consensus price target of $43.71, indicating a potential upside of 408.31%. Given Corbus Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Corbus Pharmaceuticals is more favorable than BioNxt Solutions.

Summary

Corbus Pharmaceuticals beats BioNxt Solutions on 9 of the 13 factors compared between the two stocks.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

About BioNxt Solutions

BioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.